Dissertations / Theses on the topic 'Bromocriptine'
To see the other types of publications on this topic, follow the link: Bromocriptine.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 38 dissertations / theses for your research on the topic 'Bromocriptine.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.
1
LE, POMMELET CHRISTOPHE. "Sandostatine et bromocriptine dans l'acromegalie." Aix-Marseille 2, 1992. http://www.theses.fr/1992AIX20840.
Full text
2
Pagnacco, Marie. "Le traitement des prolactinomes par bromocriptine retard." Université Louis Pasteur (Strasbourg) (1971-2008), 1992. http://www.theses.fr/1992STR1M031.
Full text
3
BOSSUT, JEAN-LOUIS. "Traitement des prolactinomes par la bromocriptine injectable : a propos d'une etude retrospective sur 23 patients." Lille 2, 1994. http://www.theses.fr/1994LIL2M307.
Full text
4
Lucia, Christine. "Pleuropneumopathies à la bromocriptine : discussion sur un cas." Montpellier 1, 1991. http://www.theses.fr/1991MON11209.
Full text
5
BERTHET, EVELYNE. "Les macroprolactinomes et leur traitement : role de la bromocriptine." Lyon 1, 1989. http://www.theses.fr/1989LYO1M486.
Full text
6
Odenthal, Maria Esther. "Uso da bromocriptina e da dexametasona na interrupção da gestação em cadelas." Universidade Federal de Viçosa, 2003. http://locus.ufv.br/handle/123456789/5170.
Full textAbstract:
Made available in DSpace on 2015-03-26T13:47:20Z (GMT). No. of bitstreams: 1
texto completo.pdf: 235255 bytes, checksum: e59ffc4b4d93eb2387e5b1f9aaefaf2a (MD5)
Previous issue date: 2003-12-16With the goal of evaluating the efficacity of bromocriptine and dexametazone, 30 mongrel bitches, with more than 35 days of pregnancy confirmed by ultrasonography, clinicaly healthy, with weights varying between 10 and 30 kgs, were divided in three groups: Group 1 - Underwent treatment with bromocriptine for 6 days with a dosage of 0,03 mg/kg every 12 hours; Group 2 Underwent treatment with dexametasone for 10 days with a dosage of 0,2 mg/kg every 12 hours; Group 3 control. The results demonstrated that both the animals treated with bromocriptine as well as those treated with dexametasone had their pregnancies interrupted in 90% of the cases. In the conditions in which the present experiment was made, no serious endometrial alterations, with endangerment of uterine phisiology, were observed. It was verified that the abortion happens later in the group treated with dexametasone, where the phoetus expulsion may occur up to the 10th day after the treatment.
Objetivando avaliar o efeito abortivo de bromocriptina e da dexametasona, 30 cadelas sem raça definida, com mais de 35 dias de gestação, confirmada por ultrasonografia, clinicamente sadias, com peso variando entre 10 e 30 kg foram separadas em três grupos, a saber: Grupo 1 - Submetidas ao tratamento com bromocriptina durante 6 dias na dose de 0,01 mg/kg a cada 12 horas; Grupo 2 - Tratadas com dexametasona durante 10 dias na dose de 0,02 mg/kg a cada 12 horas; Grupo 3- Controle. Os resultados demonstraram que tanto os animais tratados com bromocriptina, como aqueles tratados com dexametasona tiveram suas gestações interrompidas em 90% dos casos. Na condição em que foi realizado o presente experimento, não foram observadas alterações endometriais graves, que pudessem comprometer a fisiologia uterina. Verificou-se que o abortamento é mais tardio no grupo tratado com dexametasona com a expulsão do feto pode ocorrer até o 10o dia após o início do tratamento.
7
MARTINET, JEAN-PIERRE. "Adjonction de bromocriptine a un traitement par neuroleptique chez des patients schizophrenes resistants." Rennes 1, 1992. http://www.theses.fr/1992REN1M014.
Full text
8
SARRAIL, ERIC. "Boromocriptine et hyponatremie." Toulouse 3, 1992. http://www.theses.fr/1992TOU31035.
Full text
9
COUSINIE, VERONIQUE. "Comparaison de la bromocriptine et de la levodopa dans le traitement de premiere intention de la maladie de parkinson : comparaison des effets secondaires de la leovodpa chez des patients traites par levodopa ou bromocriptine plus levodopa." Toulouse 3, 1991. http://www.theses.fr/1991TOU31059.
Full text
10
Brue, Thierry. "La prolactine humaine, aspects physiopathologiques ; resistance des prolactinomes a la bromocriptine et heterogeneite moleculaire de la prolactine." Aix-Marseille 2, 1995. http://www.theses.fr/1995AIX20652.
Full text
11
GELIN, VALERIE. "Psychoses puerperales : a propos du role de la bromocriptine dans deux cas de manie du post-partum." Lyon 1, 1992. http://www.theses.fr/1992LYO1M324.
Full text
12
Dupin, Anne Claude. "Ischémies artérielles aigues et bromocriptine dans le post-partum : à propos de 5 cas." Montpellier 1, 1996. http://www.theses.fr/1996MON11026.
Full text
13
Bouton, Marcia E., Lisa M. Winton, Sonal G. Gandhi, Lakshmi Jayaram, Prahladbhai N. Patel, Patrick J. O’Neill, and Ian K. Komenaka. "Temporal resolution of idiopathic granulomatous mastitis with resumption of bromocriptine therapy for prolactinoma." ELSEVIER SCI LTD, 2015. http://hdl.handle.net/10150/622576.
Full textAbstract:
INTRODUCTION: Idiopathic granulomatous mastitis (IGM) is becoming more commonly recognized and reported more often. Currently, many recommend corticosteroids in its management. PRESENTATION OF CASE: A 34-year-old G3P2 Hispanic female, 28 weeks pregnant, presented with a 19 cm right breast mass. She had a known prolactinoma treated with bromocriptine which was discontinued during her pregnancy. Ultrasound guided core biopsy procedure revealed granulomatous mastitis. The patient was told that the mass would resolve with observation. The patient seen at another institution by an infectious disease specialist who started treatment with amphotericin for presumptive disseminated coccidioidomycosis. Repeated titers were negative for coccidioides antibody. Repeat cultures were negative as well. Due to the persistence of the infectious disease specialist, tissue cultures were performed on fresh tissue specimens, which did not grow bacterial, fungal, nor acid fast organisms. The amphotericin regimen resulted in no improvement of her breast mass after 10 weeks. Within two weeks of stopping the antifungal therapy, however, the mass diminished to 6 cm. The patient delivered at 39 weeks. Bromocriptine was restarted, and within 4 weeks, the lesion was no longer palpable. She had not shown signs of recurrence for 32 months. DISCUSSION: Treatment recommendations for IGM vary widely but antibiotics and antifungal medications are not recommended. Corticosteroid treatment is most commonly recommended, however, outcomes may not be different from management with observation. Prolactin may be involved in the pathophysiology of the process. CONCLUSION: IGM is becoming recognized more frequently. Observation and patience with natural history can be an effective management. (C) 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd.
14
Blot, Isabelle. "Effets du Parlodel L. A. R sur les macroprolactinomes : à propos de sept cas." Bordeaux 2, 1991. http://www.theses.fr/1991BOR2M033.
Full text
15
Llorca, Pierre-Michel. "Efficacite comparee de la carbamazepine, de la bromocriptine, et de la cyproheptadine en traitement adjuvant aux neuroleptiques chez 24 patients schizophrenes chroniques resistants." Aix-Marseille 2, 1991. http://www.theses.fr/1991AIX20953.
Full text
16
Sajas, Christiane. "Traitement des hyperprolactinémies primaires par le CV 205-502." Montpellier 1, 1990. http://www.theses.fr/1990MON11154.
Full text
17
Furigo, Isadora Clivatti. "Estudo do mecanismo de ação da bromocriptina e de antagonistas de prolactina no tratamento do Diabetes Mellitus tipo 2 e da obesidade." Universidade de São Paulo, 2016. http://www.teses.usp.br/teses/disponiveis/42/42137/tde-16052017-145647/.
Full textAbstract:
Atualmente, é crescente o interesse em estudar o potencial do Sistema Nervoso Central (SNC) como alvo de medicamentos antidiabéticos, uma vez que ele possui receptores de insulina e desempenha papel crítico na regulação da homeostase glicêmica. Nesse sentido, o Cycloset® (mesilato de bromocriptina de liberação rápida), um medicamento de ação central aprovado nos Estados Unidos para o tratamento do DMT2, atende a essa tendência atual. Trabalhos prévios mostram efeitos benéficos da bromocriptina (Bromo) sobre a hiperglicemia e hiperlipidemia em modelos de animais obesos tratados com essa droga. Por ser um agonista dopaminérgico, um dos possíveis mecanismos de ação dessa droga pode ser bloqueando a liberação e produção de prolactina (Prl). Níveis elevados de prolactina na circulação sanguínea, observados tanto em indivíduos com prolactinomas como em pessoas tratadas com medicamentos que causam hiperprolactinemia, geram anormalidades no metabolismo de carboidratos e lipídeos, o que pode levar a um quadro de síndrome metabólica. Na presente tese, testamos a hipótese de que ao menos parte dos efeitos antidiabéticos da Bromo seja mediada pela inibição da secreção de prolactina. Avaliamos os efeitos do tratamento com Bromo em camundongos machos e fêmeas geneticamente obesos e resistentes à insulina (ob/ob), bem como testamos se os efeitos benéficos do medicamento seriam revertidos com a reposição de Prl. Machos tratados com Bromo apresentaram maior sensibilidade à insulina, enquanto que a reposição de Prl manteve os animais menos sensíveis, tais como os animais do grupo controle. As fêmeas tratadas com Bromo apresentaram tendência à melhora de sensibilidade à insulina, bem como foram mais tolerantes à glicose, sendo que a reposição de Prl em animais tratados com Bromo também reverteu o efeito benéfico do medicamento. Dessa forma, demonstramos que ao menos parte dos efeitos antidiabéticos da Bromo é mediada pela inibição da secreção basal de Prl. Em um segundo conjunto de experimentos, testamos se a administração de antagonistas de prolactina (G129R-hPrlR) em machos ob/ob, por vias centrais ou periféricas, produziria efeito antidiabético. Observamos que tanto o tratamento periférico como o central diminui a curva glicêmica dos animais em testes de tolerância à glicose e melhoram a sensibilidade à insulina, embora ainda não tenhamos obtido valores significativos devido a nossa amostragem. Por fim, investigamos se a ação da Prl sobre o metabolismo ocorre por meio da interação com o receptor de estrógeno alfa (ERα). Verificamos que receptores de prolactina e de ERα são expressos em áreas comuns no SNC e que variações nos níveis circulantes de estrógeno causam mudanças na sensibilidade à prolactina. Portanto, no presente trabalho, identificamos o possível mecanismo pelo qual a Bromocriptina promove melhorias no controle glicêmico e, de forma inédita, produzimos evidências que o uso de antagonistas de prolactina pode ter potencial no tratamento do DMT2.Type 2 Diabetes mellitus (T2DM) is a syndrome characterized by dysfunctions in the metabolism of glucose, amino acids and free fat acids. Although most of the drugs currently used to treat T2DM targets peripheral organs, a growing interest in studying the Central Nervous System (CNS) as a potential target of antidiabetic drugs is appearing. The CNS possesses insulin receptors and plays a critical role in regulating glucose homeostasis. In this sense, Cycloset® (quick release bromocriptine mesylate) a drug that acts on CNS, was recently approved in United States to treat T2DM. Previous studies have shown beneficial effects of bromocriptine (Bromo) on hyperglycemia and hyperlipidemia in obese animal models. As a dopaminergic agonist, a possible mechanism of action of this drug could be caused by a decreased prolactin (Prl) production and release. High serum prolactin levels, as observed in patients bearing prolactinomas or individuals using drugs that induce hyperprolactinemia, generate abnormalities in carbohydrate and lipid metabolism, which can lead to metabolic syndrome. In the current thesis, we tested the hypothesis that part of bromocriptine antidiabetic effects is due to an inhibition of prolactin secretion. We evaluated Bromo effects in genetically obese and insulin resistant male and female mouse (ob/ob), as well as we tested whether replacing Prl could reverse the beneficial effects of Bromo. Males treated with Bromo showed lower insulin resistence, whereas Prl replacement decreased insulin sensitivity. Females treated with Bromo showed tendency towards an improvement in their insulin sensitivity and glucose tolerance. Prl replacement also reversed the beneficial effects of Bromo in this group. Thus, we demonstrated that at least part of the antidiabetic effects of Bromo is due to inhibition of Prl secretion. In another set of experiments, we tested whether central or peripheral treatment with prolactin antagonists (G129R-hPrlR) causes antidiabetic effects in ob/ob male mice. Both peripheral and central treatment decreased the glycemic curve during glucose and insulin tolerance tests, although we still did not obtain statistically significant values with our sample size. Lastly, we investigated whether metabolic Prl action occurs due to a putative interaction with estrogen receptor alpha (ERα). We found a wide co-expression between Prl receptor and ERα in the CNS. Additionally, changes in estrogen levels decrease prolactin sensitivity. Therefore, in the present study we identified the possible mechanism by which bromocriptine promotes improvements in glycemic control, and for the first time, we obtained evidence that the use of prolactin antagonists can have a potential effect in the treatment of T2DM.
18
Dahlen, Josiane. "Mise au point du dosage de la bromocriptine par radiorécepteur-essai application pharmacocinétique et clinique." Grenoble 2 : ANRT, 1986. http://catalogue.bnf.fr/ark:/12148/cb37596887m.
Full text
19
FORCE, MARIBEL. "Action de la levodopa et de la bromocriptine sur le debit sanguin cerebral du parkinsonien." Toulouse 3, 1988. http://www.theses.fr/1988TOU31205.
Full text
20
Dahlen, Josiane. "Mise au point du dosage de la bromocriptine par radiorécepteur-essai : application pharmacocinétique et clinique." Strasbourg 1, 1986. http://www.theses.fr/1986STR13113.
Full text
21
Hanneman, Jessica Marie. "EFFECTS OF ENDOPHYTE-INFECTED TALL FESCUE SEED AND BROMOCRIPTINE ON ENDOCRINE AND IMMUNE FUNCTION IN HORSES." UKnowledge, 2018. https://uknowledge.uky.edu/gluck_etds/38.
Full textAbstract:
Consumption of endophyte-infected (E+) grasses has long been associated with health problems in animals. In cattle E+ tall fescue consumption leads to fescue toxicosis, and in horses it leads reproductive problems. The health-related issues associated with endophyte consumption have been attributed to the effects caused by the ergot alkaloids produced by the fungus. These ergot alkaloids are considered D2-like receptor agonists, and 5-HT2 serotonin and α-adrenergic receptor partial agonists. Many studies in humans, swine, cattle, and horses have identified that ergopeptines cause a decrease in prolactin production due to their dopaminergic activities. Additionally, these molecules have been found to cause vasoconstriction in cattle and horses through their other agonistic activities. Furthermore, dopamine agonists are currently being used to treat pituitary pars intermedia dysfunction (PPID) in horses, a condition in which the horse lacks sufficient dopamine. However, the ergot alkaloids found in E+ tall fescue had not previously been investigated for their potential benefits in treating PPID horses. Moreover, little research has investigated the effects of ergot alkaloids and dopamine agonists on the immune system of horses, even though many health problems associated with E+ tall fescue consumption suggest there to be an elicited inflammatory response. Thus, the primary objective of this study was to establish an understanding of immune and hormone responses to ergot alkaloids and dopamine agonists in the horse. The hypothesis of this body of research was that ergot alkaloids and bromocriptine both would elicit inflammatory and hormone responses in the horse. Specifically, this research was conducted to determine the effects of E+ tall fescue seed consumption on immune, hormone, and vasoconstrictive responses, in both non-PPID and PPID horses. In addition, both the in vitro and in vivo effects of bromocriptine on cytokine production from equine peripheral blood mononuclear cells (PBMCs) were investigated. In the first study, there were no significant changes in body morphometrics, vasoconstriction, hormone responses or cytokine expression due to the consumption of ergot alkaloids in non-PPID and PPID horses. The second study was an in vitrostudy in which PBMCs were exposed to varying concentrations of either bromocriptine, a D2-like receptor agonist that is used as a model for ergot alkaloid consumption, or dopamine. This experiment demonstrated that exposure to dopamine or a dopamine agonist at a concentration greater than 10-5M is toxic to PBMCs, and that bromocriptine elicits an anti-inflammatory effect at concentrations less than 10-5M. Concentrations of dopamine less than 10-5M, on the other hand, did not cause any significant changes in cytokine expression. A third study was conducted that evaluated the effects of an intravenous injection of bromocriptine on hormone and immune responses in the aged mare. This study identified that bromocriptine maximally reduced prolactin levels 12 hours post-injection and prolactin returned to baseline levels approximately 56 hours post-injection. Additionally, only a significant increase in IL-1β was detected 12 hours post-injection, which suggests bromocriptine was activating an innate immune response. Overall, the body weights and rectal temperatures of horses did not significantly change in any of the experiments, which indicated that aged non-pregnant horses are able to tolerate E+ tall fescue. In addition, this body of research identified that intravenous delivery of a semi-synthetic dopamine agonist, bromocriptine, and not an oral delivery of an E+ tall fescue seed derived dopamine agonist, caused a decrease in prolactin concentrations, but revealed conflicting results regarding inflammatory responses. In summary, further research is warranted to determine the mechanism of action that dopamine agonists have on the immune system of horses.
22
Vautier, Sarah. "Etude de l'influence d'une pompe d'efflux, la P-glycoprotéine, sur le transport intracérébral des médicaments antiparkinsoniens : Application à l'aide de modèles in vitro et in vivo." Paris 11, 2008. http://www.theses.fr/2008PA114847.
Full textAbstract:
La bromocriptine est un médicament antiparkinsonien responsable de troubles de la vigilance dus à une plus forte pénétration cérébrale du médicament. La P-glycoprotéine (Pgp/ABCB 1) est une pompe d'efflux ATP-dépendante présente au niveau des organes qui assure la protection de l'organisme vis-àvis des xénobiotiques et freine le passage intracérébral des médicaments. Nous avons démontré que la bromocriptine est substrat de la Pgp, in vitro et chez la souris. D'autre part, la bromocriptine est capable d'inhiber son activité in vitro. Enfin, dans un modèle murin de neurodégénérescence dopaminergique la bromocriptine s'est accumulée au niveau cérébral. Ces résultats laissent présager des interactions médicamenteuses entre bromocriptine et d'autres médicaments substrats de la Pgp. De ce fait, la connaissance de la fonctionnalité de la Pgp chez le patient parkinsonien devient une donnée importante pour prévoir la neurobiodisponibilité et la neurotoxicité des médicaments substratsBromocriptine is an antiparkinsonian drug that leads to excessive daytime sleepiness, hallucination or confusion, due to brain accumulation. P-glycoprotein (Pgp/ ABCB 1) is an ATP binding cassette transporter involved in drug phannacokinetics and plays a role in detoxification against xenobiotics. At the blood brain barrier Pgp leads to extrusion of its substrates in cerebral blood flow. We show that bromocriptine is a Pgp substrate in vitro an in vivo in mice, and inhibitor in vitro. Ln a murine model of dopaminergic degeneration, bromocriptine bram transport is increased. Bromocriptme is a potential drug for medicinal interactions. Knowledge of Pgp functionality and/or expression could be useful to anticipate prescription of Pgp substrates and avoid neurotoxicity in treatment of Parkinson' s disease
23
Montgaillard, Joe͏̈lle. "Hyperprolactinémiant (sulpiride), hypoprolactinémiant (bromocryptine) et cancer du sein." Montpellier 1, 1988. http://www.theses.fr/1988MON11132.
Full text
24
Alaoui, Katim. "Contribution à l'étude des effets cardiovasculaires des agonistes dopaminergiques et de leurs mécanismes d'action chez le rat." Bordeaux 2, 1989. http://www.theses.fr/1989BOR2B002.
Full text
25
Durocher, Alexandra. "Microdialyse tissulaire "in vivo" : intérêt en pharmacocinétique. Application : détermination du profil pharmacocinétique de la bromocriptine dans le striatum de rat par microdialyse cérébrale." Paris 5, 1995. http://www.theses.fr/1995PA05P137.
Full text
26
Matsubayashi, Keiko. "Contribution of cytochrome P450 3A pathway to bromocriptine metabolism and effects of ferrous iron and hypoxia-reoxygenation on its elimination in the perfused rat liver." Kyoto University, 1997. http://hdl.handle.net/2433/202219.
Full text
27
Mello, Ana Lucia Rocha Beltrame de. "Efeitos da bromocriptina na prevenção da síndrome do hiperestímulo ovariano precoce em mulheres de alto risco submetidas a fertilização in vitro." Universidade de São Paulo, 2009. http://www.teses.usp.br/teses/disponiveis/5/5139/tde-23032010-101729/.
Full textAbstract:
Objetivo: Avaliar o uso da bromocriptina na prevenção da síndrome do hiperestímulo ovariano (SHO) precoce moderada ou grave em mulheres de alto risco submetidas a fertilização in vitro. Pacientes e Métodos: Estudo duplo-cego, prospectivo e randomizado, foi realizado entre fevereiro de 2006 e novembro de 2007 no Centro de Reprodução Humana da Divisão de Ginecologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, na Huntington Centro de Medicina Reprodutiva e no Centro de Reprodução Humana do Hospital e Maternidade Santa Joana. Foram estudadas 28 mulheres entre 20 e 39 anos de alto risco para desenvolver a SHO (presença de 20 folículos ou mais ao ultrassom transvaginal no dia anterior à administração de gonadotrofina coriônica humana (hCG); níveis séricos de estradiol no dia da administração do hCG ou previamente a esta data iguais ou maiores que 3000 pg/ml e/ou aumento significativo ovariano bilateral). Foram divididas randomicamente, em dois grupos: A (n=17) e B (n=11), que receberam, respectivamente, um comprimido diário de ácido fólico (2,0 mg) e de bromocriptina (2,5 mg), por via oral, durante 14 dias, com início no dia da administração de hCG. As pacientes foram avaliadas no dia da administração do hCG (D1) e sete dias após (D2), quando foram realizados : ultrassom abdominal para verificar a presença de ascite; coleta de sangue para dosagens séricas de hemoglobina, hematócrito, leucócitos, plaquetas, uréia, creatinina, TGO, TGP e do fator de crescimento endotelial vascular (VEGF), e coleta de urina de 24 h para determinação de clearance de creatinina e concentração urinária de sódio. Resultados: Da série total (28 pacientes) que concluíram todo o estudo, 14 apresentaram ascite em D2, das quais 10 pertenciam ao grupo A (58,8%) e 4 (36,4%) ao grupo B (p=0,246). Destas 14 pacientes, 7 preencheram os critérios de gravidade, sendo que 6 pertenciam ao grupo A e, somente uma, ao grupo B. Observou-se aumento dos valores médios de VEGF no Grupo A (134,93 pg/ml) em D2, enquanto no Grupo B, houve diminuição (119,11pg/ml) (p=0,462).Conclusões: A bromocriptina não preveniu a SHO precoce moderada ou grave em pacientes de alto risco submetidas a fertilização in vitro, no entanto, houve diminuição da quantidade de líquido intraperitoneal e dos níveis séricos de VEGF.Objective: To evaluate the effect of bromocriptine for the prevention of either early moderate or severe ovarian hyperstimulation syndrome (OHSS) in high risk women submitted to in vitro fertilization. Patients and Methods: A double-blind, prospective, randomized study was carried out between February 2006 and November 2007 at the Human Reproduction Center, Department of Gynecology, Teaching Hospital of the School of Medicine, University of São Paulo, at the Huntington Center of Reproductive Medicine and at the Human Reproduction Center of Santa Joana Hospital and Maternity Home. Twenty-eight women between 20 and 39 years of age, considered high risk for the development of OHSS (presence of 20 follicles at transvaginal ultrasonography on the day prior to human chorionic gonadotrophin [hCG] administration; serum estradiol levels 3000 pg/ml prior to or on the day of hCG administration and/or a significant bilateral increase in ovarian diameter), were included. The participants were randomly allocated to one of two groups. Women in group A (n=17) took a 2.0 mg tablet of folic acid and women in group B (n=11) took a 2.5 mg tablet of bromocriptine. Both treatments were taken orally daily for 14 days beginning on the day of hCG administration. Patients were evaluated on the day of hCG administration (D1) and seven days later (D2) at which time the following tests were performed: abdominal ultrasonography to detect the presence of ascites; blood sampling for the assessment of hemoglobin, hematocrit, leukocytes, platelets, urea, creatinine, SGOT, SGPT and vascular endothelial growth factor (VEGF). In addition, a 24-hour urine sample was collected to determine creatinine clearance and urinary sodium concentration. Results: All patients concluded the study. Fourteen had ascites at D2, 10 in group A (58.8%) and 4 (36.4%) in group B (p=0.246). Of these 14 patients, 7 fulfilled the criteria for severe OHSS, 6 in group A and 1 in group B. An increase was identified in mean VEGF values in group A (134.93 pg/ml) at D2, while a reduction was found in group B (119.11 pg/ml) (p=0.462). Conclusions: Bromocriptine did neither prevent early moderate nor severe OHSS in high risk patients submitted to in vitro fertilization; however, a reduction occurred in the intraperitoneal fluid volume and in serum VEGF levels.
28
Guarnieri, Regina Vieira [UNIFESP]. "Modulação dopaminérgica D2 dos processos envolvidos em falsas memórias." Universidade Federal de São Paulo (UNIFESP), 2014. http://repositorio.unifesp.br/handle/11600/23229.
Full textAbstract:
Made available in DSpace on 2015-12-06T23:46:42Z (GMT). No. of bitstreams: 0
Previous issue date: 2014Associação Fundo de Incentivo à Psicofarmacologia (AFIP)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Estudos em humanos e em animais indicam que o sistema dopaminergico esta envolvido com a cognicao, onde se incluem processos mnemonicos e atencionais como troca de foco de atencao, atencao executiva e particularmente, atencao seletiva. No entanto, pouco se estudou sobre a acao dopaminergica sobre a memoria emocional ou os seus efeitos sobre a producao de falsas memorias. Objetivos: avaliar o papel dos receptores dopaminergicos do subtipo D2, por meio da administracao aguda de farmacos seletivos para os mesmos, nas memorias verdadeiras e falsas. Metodo: este estudo foi duplo-cego, randomizado, em grupos paralelos de tratamento, controlados com placebo. Realizou-se com sujeitos jovens, saudaveis, do sexo masculino. Os tratamentos envolveram doses unicas e equipotentes em termos cognitivos do haloperidol (antagonista dopaminergico D2, 4 mg), bromocriptina (agonista dopaminergico D2, 2,5 mg) e sulpirida (antagonista dopaminergico D2, 200 mg e 400 mg) administrados via oral. A bateria de testes envolveu a avaliacao dos efeitos destes farmacos sobre o julgamento emocional do estimulo (SAM), a memoria verdadeira e falsa utilizando figuras do IAPS adaptadas para estudo de falsas memorias (DRM-IAPS) e listas de palavras associadas com conteudo neutro e emocional (procedimento DRM). Alem disso, foram aplicados testes de atencao, de humor, de memoria operacional, funcoes executivas e memoria logica. Resultados: Em geral, o maior indice de falsas memorias se deu nos blocos neutros e o menor indice nos blocos positivos em todos os grupos. As diferencas de grupos quanto ao efeito da manipulacao dopaminergica nas memorias verdadeiras e falsas, entretanto, foram encontradas para os estimulos que apresentavam carga emocional. A ativacao e o bloqueio dopaminergico causaram prejuizo no desempenho da memoria verdadeira e aumento do indice de falsas memorias, respectivamente
CNPq: 141383/2010-0
BV UNIFESP: Teses e dissertações
29
Oliveira, Miriam da Costa. "Acoes do tamoxifen : acetato de noretisterona e bromocriptina sobre a morfologia e funcao lactotrofica de hipofises de ratas com hiperprolactinemia induzida pelo estradiol." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 1992. http://hdl.handle.net/10183/164142.
Full text
30
Lii, Wei-Sheng, and 李維生. "Effects of Bromocriptine and Photoperiod on Puberty in Gilts." Thesis, 1997. http://ndltd.ncl.edu.tw/handle/42762497511852467445.
Full textAbstract:
碩士東海大學
畜產學研究所
85
Two experiments were conducted to determine effects of bromocriptine ( a dopaminergic agonist ) injection and photoperiod regimen on puberty in gilts. In Exp. I., 36 crossbred gilts【 Yorkshire×Landrace ( YL ) and Duroc× Yorkshire×Landrace ( DYL ) 】born on February 10-12,1995, were randomly allotted into control ( C? K, bromocriptine ( BRO ) or melatonin ( MEL ) group on 60 d of age. Gilts in CTL group were exposed to natural photoperiod. Those in BRO group were exposed to natural photoperiod, but were injected intramuscularly with bromocriptine mesilate ( 0.5 mg/ Kg ) on 165,195 and 225 d of age. Those in MEL group were administered melatonin orally at dose of 3 mg/ day from 90 d of age to the end of this Exp. All gilts were collected blood samples twice a week from 165 d of age for the determination of progesterone by radioimmunoassay to evaluate whether the individual gilt ovulated before first estrus. The proportions of gilts attaining puberty within 245 d were 7/12, 4/12 and 3/12 for CTL, BRO and MEL groups, respectively, without significant difference among treatments. The proportion of gilts attaining puberty in MEL group tended to be lower than that in CTL group ( p=0.098 ). Ages at puberty and body weights at puberty were not different among treatments. In Exp. II, 36 crossbred gilts born on August 27-28, 1995, were randomly allotted into CTL, BRO or long-light ( LL ) group on 65 d of age. Treatments for CTL and BRO groups were the same as described in Exp. I. Gilts in LL group were exposed to 16 h photoperiod from 120 d of age to the end of this Exp. The proportions of attaining puberty were not different among treatments ( 6/12, 6/12 and 5/12, for CTL, BRO and LL groups, respectively ). However, LL group ( 181.4±24.4d ) attained puberty earlier significantly than CTL group ( 216.2±12.4d ) ( p<0.05 ). Body weights at puberty were not different among treatments. It is concluded that the bromocriptine injection doesn*t influence the proportion and age of puberty in gilts. Melatonin administration decreases the proportion of puberty in gilts during decreasing daylength, and longdays advances puberty in gilts during increasing daylength.
31
Shiau, Jin-Chyuan, and 蕭金泉. "Effect of Bromocriptine Injection on Reproductive Performances of Summer." Thesis, 1995. http://ndltd.ncl.edu.tw/handle/49742042378371335207.
Full textAbstract:
碩士東海大學
畜牧學系
83
This study was conducted to evaluate the effects of bromocriptine (a dopaminergic agonist) injection on reproductive performances of weaned sows in summer. In trail I, the incidence of post-weaning anestrus in each month from January 1994 to December 1994 was surveyed in a commercial pig farm in central Taiwan. The number of surveyed sows was 104 -171 in each month. Results showed that the incidences of anestrus within 10 days after weaning were high in July, August and September (28.1, 22.4 and 21.4%, respectively), and low in January, February, November and December (all below 5%). Fourty- six estrous sows in July and August were collected blood samples on Day 10 post-weaning for the detection of progesterone by RIA. Results showed that 16 (34.8%) of them possessed corpus lutea (P4 > 1.9 ng/ml). In trail II, 37 multiparous crossbred sows (LY or YL) weaning after a 28-day lactation were randomly allotted into either control group (n=19) or treament group (n=18) in July and August. Sows in treament group were injected intramuscularly with bromocriptine mesilate (50 mg/head) on the day of weaning. All of 18 (100%) sows in treament group showed a detectable heat within 10 days after weaning, while only 14 of 19 (73.7%) sows in group showed heat in the period (p < 0.05). However, there were significant differences ( p > 0.05) between groups in conception rates, farrowing rates, and litter size (control vs treament; vs 94.4%, 71.4% vs 83.3%, and 9.5±1.1 vs 9.3±0.6, It is concluded that the bromocriptine injection can overcome the promblem for the anestrus of weaned sow in summer.
32
Weng, Yuan-Cheng, and 翁源成. "Application of Methotrexate and Bromocriptine in Termination of Pregnancy in Bitches." Thesis, 1997. http://ndltd.ncl.edu.tw/handle/29220415332380651915.
Full textAbstract:
碩士國立中興大學
獸醫學系
85
Methotrexate (MTX) and bromocriptine (BrC) were used in this study for terminating pregnancy in bitches. MTX can block DNA synthesis. BrC can inhibit prolactin secreetion and decrease serum pregesterone conxentration. Blood count, serum biochemistry, and serum pregesterone concentrations were analyzed in five normal pregnant bitches, five MTX (5 mg/M2) treated bitches,and eight MTX (5 mg/M2) treated bitches in 5, 15, 25, 38 days of pregnancy.Strong side effects were found in MTX treated bitches, especially in bitches with 25 or 38 day of pregnancy. None of the eight pregnant bitches terminated their pregnancy after MTX treatment. Four ultrasound confirmed pregnant bitcheswere treated with BrC (0.1 mg/Kg). Serum progesterone concentrations weredecreased immediately after the first day of BrC treatment. Three bitches (40to 50 day of pregnancy) were aborted within 2 or 3 days after BrC Treatment. The fetus ultrasound image of a 30-day-pregnant bitch was undertectable aftera 6 day BrC treatment. BrC is proved useful in terminating mid or late pregnancy in bitches..
33
Barra, Cátia Isabel de Almeida. "Effect of Bromocriptine in improving Non-alcoholic Fatty Liver Disease in obese animal model of Type 2 Diabetes." Master's thesis, 2019. http://hdl.handle.net/10316/97654.
Full textAbstract:
Trabalho Final do Mestrado Integrado em Medicina apresentado à Faculdade de MedicinaA Bromocriptina, agonista D2 da dopamina, foi aprovada pela FDA para melhorar a sensibilidade à insulina e a Diabetes tipo 2 e pode ter benefícios nas patologias associadas como a Doença do Fígado Gordo não Alcoólico (NAFLD). Embora os mecanismos subjacentes ainda não sejam conhecidos, a Bromocriptina pode ter um efeito direto sob vários órgãos insulino-dependentes. Este estudo avaliou a melhoria da sensibilidade à insulina e a reversão da esteatose hepática num modelo animal obeso e diabético tipo 2. Os ratos Wistar (W) foram alimentado com uma dieta normal e os ratos Goto-Kakizaki (GK) diabéticos não obesos foram divididos em 4 grupos distintos: GK com dieta normal, GK com obesidade induzida por dieta calórica, GK obesos tratados com Bromocriptina 10mg/kg/dia durante 30 dias e GK obesos tratados com veículo. Os perfis glicémico e lipídico assim como a sinalização da insulina e dopaminérgica no fígado foram avaliados em jejum. As formas fosforiladas do IR e da AMPK foram também avaliadas 1h após a ingestão de uma dieta mista. Para além disto, também foi realizada a coloração do tecido hepático com Hematoxilina-Eosina (HE), assim como registado o peso do fígado e quantificados dos triglicerídeos hepáticos. Os ratos alimentados com dieta calórica revelaram níveis maiores de glicémia em jejum e trigliceridémia, os quais foram revertidos após a administração da Bromocriptina. No fígado verificou-se uma evidente redução da esteatose hepática e dos triglicerídeos hepáticos, aumento dos níveis de IR em jejum, diminuição do IRβ(Tyr1361) no período pós-prandial e diminuição do GLUT2 nos ratos tratados com Bromocriptina, sugerindo uma alteração no metabolismo da glucose e dos lípidos. Além disso, houve um aumento dos níveis de D1R e da TH em jejum e não se verificaram alterações nos níveis de D2R e DARPP32. Os nossos resultados sugerem que a Bromocriptina atua diretamente no fígado modulando a sinalização dopaminérgica, a qual está associada a um aumento dos níveis de IR em jejum e à reversão da esteatose hepática. Embora sejam necessários mais estudos, estes resultados indicam que a Bromocriptina altera o metabolismo da glicose e dos lípidos, o que pode ser eficaz na redução da lipotoxicidade hepática.
The D2 agonist Bromocriptine was approved by the FDA to improve insulin sensitivity and Type 2 Diabetes and may have beneficial effects in associated pathologies like Non-alcoholic Fatty Liver Disease (NAFLD). Although the underlying mechanisms remain unclear, Bromocriptine may have a direct effect on various insulin-sensitive organs. This study evaluated the improvement of insulin sensitivity and reversion of hepatic steatosis in an animal model of obese type 2 diabetes. Wistar (W) rats fed a normal diet and non-obese type 2 diabetic Goto-Kakizaki (GK) rats were divided into 4 groups: GK with normal diet, GK with obesity induced by a high fat and sucrose diet, GK obese treated with Bromocriptine 10 mg/kg/day for 30 days and obese GK treated with vehicle. The glycaemic and lipid profiles and insulin and dopamine signalling in liver were evaluated at fasting. Phosphorylated forms of IR and AMPK were also evaluated 1h after a mixed diet ingestion. In addition, Hematoxylin-Eosin staining of liver was performed, as well as the liver weight and hepatic triglycerides quantification. Rats maintained on a fat diet revealed a worsening of fasting glycemia and plasma triglycerides which were reverted with the administration of Bromocriptine. In the liver, there was an evident reduction of hepatic steatosis and hepatic triglycerides, increase IR levels in fasting, decrease of IRβ(Tyr1361) in post prandial period and decrease of GLUT2 levels in Bromocriptine-treated rats, suggesting a remodeling of glucose and fatty acid metabolism. Moreover, there was an increase in D1R and TH levels and no alterations were observed in D2R and DARPP32 levels. Our results suggest that Bromocriptine acts directly in the liver modulating dopamine signalling, which is associated with an increase of IR and a reduction of hepatic steatosis. Although further studies are still required, our results suggest that Bromocriptine improves glucose and lipid metabolism and may be effective in reducing hepatic lipotoxicity.
FCT
34
Marques, Daniela Filipa Pereira. "A Bromocriptina como moduladora do metabolismo lipídico no tecido adiposo e da sensibilidade à insulina na Diabetes Mellitus tipo 2." Master's thesis, 2017. http://hdl.handle.net/10316/81914.
Full textAbstract:
Dissertação de Mestrado em Patologia Experimental apresentada à Faculdade de MedicinaIntrodução e Objetivos: A obesidade está associada ao desenvolvimento de insulino-resistência e disfunção do tecido adiposo, conduzindo a alterações do metabolismo lipídico e glicémico, e em última instância, diabetes tipo 2 (DMT2). A bromocriptina, um agonista dopaminérgico D2, mostrou-se promissora no tratamento da DMT2 contribuindo para a diminuição dos níveis da glicemia. No entanto, os mecanismos de ação da bromocriptina bem como a sua ação nos tecidos sensíveis à insulina não são conhecidos. Neste estudo tivemos como objetivo avaliar o potencial terapêutico da bromocriptina na modulação da sensibilidade à insulina em ratos diabéticos tipo 2 com obesidade induzida pela dieta, bem como a sua ação no tecido adiposo periepididimal (TAE).Métodos: Foram utilizados ratos Wistar (W) alimentados com dieta normal (grupo 1) e ratos Goto-Kakizaki (GK) diabéticos tipo 2 não obesos divididos em 4 grupos: GK com dieta normal (grupo 2), GK com obesidade induzida por uma dieta rica em gordura e sacarose (grupo 3 - GKHFD), GKHFD tratados com bromocriptina (10mg/Kg/dia) durante 30 dias (grupo 4 - GKHFDBr) e GKHFD tratados com veículo (grupo 5 - GKHFDVh) (n=8/grupo). Além da avaliação do perfil glicémico e lipídico, foi a avaliada a tolerância à insulina (prova de tolerância à insulina), bem como os mecanismos associados à captação e utilização da glicose e dos ácidos gordos no TAE.Resultados: Os ratos GK obesos apresentaram um agravamento da tolerância à insulina e dos níveis em jejum da glicemia, colesterol e dos triglicerídeos, em relação aos seus controlos não obesos. O tratamento com bromocriptina reduziu a intolerância à insulina, e a glicemia em jejum. No TAE, aumentou os níveis do transportador da glicose GLUT4, a expressão dos recetores dopaminérgicos D1 e D2, e de marcadores relacionados com a oxidação lipídica.Conclusões: Embora os mecanismos subjacentes sejam ainda desconhecidos, estes resultados sugerem que a bromocriptina melhora o perfil glicémico e a resistência à insulina na DMT2,aumentando a sinalização dopaminérgica no tecido adiposo e alterando o metabolismo dos ácidos gordos. Estudos futuros permitirão desvendar os mecanismos envolvidos.
Introduction and objectives: Obesity is associated with the development of insulin resistance and dysfunction of adipose tissue, leading to changes in lipid and glycemic metabolism, and ultimately type 2 diabetes (DMT2). Bromocriptine, a D2 dopaminergic agonist, has been shown to be promising in the treatment of DMTII contributing to the reduction of glycemic levels. However, the mechanisms involved as well as its action on insulin sensitive tissues are not known. Thus, our goal was to evaluate the therapeutic potential of bromocriptine in the modulation of peripheral sensitivity to insulin in an obese type 2 diabetic animal model, as well as insulin signaling in epididymal adipose tissue (TAE).Methods: Wistar (W) rats fed with normal diet (group 1) and non-obese type 2 diabetes, Goto-Kakizaki (GK) were divided into 4 groups: GK with normal diet (group 2), GK with diet-induced obesity (group 3 - GKHFD), GKHFD treated with bromocriptine (10mg / kg / day) for 30 days (group 4 - GKHFDBr) and GKHFD treated with vehicle (group 5 - GKHFDVh) (n = 8 / group). In addition to the evaluation of the glycemic and lipid profile and insulin tolerance, the mechanisms of glucose and fatty acids uptake and oxidation were evaluated in the TAE.Results: Obese GK rats had lower insulin tolerance and increased fasting levels of glucose, cholesterol and triglycerides in relation to their non-obese controls. The treatment with bromocriptine reduced insulin intolerance and fasting glycemia. In adipose tissue, the expression of GLUT4, D1 and D2 receptors, as well as markers related to lipid oxidation were also improved.Conclusions: Although the underlying mechanisms are still unknown, these results suggest that bromocriptine improves the glycemic profile and insulin resistance in DMT2 by increasing dopaminergic signaling in adipose tissue. Future studies will disclose the mechanisms involved.
FCT
35
White, Rehema Mary. "Effects of melatonin implants, bromocriptine and naloxone on the onset of puberty in ewe lambs." 1990. http://hdl.handle.net/1993/17255.
Full text
36
Brüggenolte, Christian [Verfasser]. "Der Zusammenhang zwischen den Hormonantworten von Prolaktin, Wachstumshormon und Cortisol auf den Bromocriptin-Challenge-Test und ihre Beziehung zu potentiellen Nebenwirkungen von Bromocriptin / vorgelegt von Christian Brüggenolte." 2006. http://d-nb.info/982469861/34.
Full text
37
Schumacher, Jakob. "Multiple Sklerose und Dopamin-Rezeptoren." Doctoral thesis, 2011. http://hdl.handle.net/11858/00-1735-0000-0006-B1D3-4.
Full text
38
Tavares, Gabriela Pires. "Unraveling the role of peripheral dopaminergic signaling in metabolism." Doctoral thesis, 2021. http://hdl.handle.net/10316/98623.
Full textAbstract:
Tese de Doutoramento no âmbito do Programa Doutoral Interuniversitário em Envelhecimento e Doenças Crónicas apresentada à Faculdade de Medicina da Universidade de Coimbra.Introdução: A dopamina tem importantes funções como moduladora do metabolismo ao nível do sistema nervoso central. Apesar de ser produzida nos tecidos periféricos, os seus efeitos diretos nestes tecidos ainda não são conhecidos. Este trabalho teve como objetivos: 1) estudar a ação direta da dopamina na captação da glucose e na regulação metabólica nos tecidos sensíveis à insulina; 2) estudar as alterações da sinalização dopaminérgica no tecido adiposo na diabetes; 3) estudar a modulação da sinalização dopaminérgica com bromocriptina, um agonista dos recetores de dopamina do subtipo D2, nos tecidos periféricos num modelo animal de diabetes tipo 2 e obesidade. Materiais & Métodos: Estudou-se a captação da glucose em ratos Wistar 1) in vivo, e; 2) Ex vivo em explantes de tecidos tratados com dopamina (10µM), bromocriptina (10µM), insulina e domperidona (DOMP, antagonista D2R, 50nM) e haloperidol (HAL, antagonista D2R+D1R, 500nM). Estudou-se também a ativação do recetor de insulina (InsR) e vias envolvidas no metabolismo lipídico, ex vivo, nas mesmas condições experimentais, por Western Blot. Foi analisada a expressão dos genes dos recetores de dopamina e de marcadores da função metabólica do tecido adiposo visceral (TAV) de indivíduos com obesidade, sensíveis à insulina (IS) ou insulino-resistentes (IR) de acordo com o índice modificado de insulinorresistência, Ox-HOMA2IR, níveis de glucose em jejum e da hemoglobina glicada (HbA1c). Em ratos Goto-Kakizaki (GK) com diabetes tipo 2 e mantidos com dieta hipercalórica, analisou-se a sinalização: dopaminérgica, da insulina e o metabolismo lipídico no fígado e tecido adiposo epididimal (TAE) após administração de bromocriptina (10mg/kg/dia, 28 dias, i.p). Resultados: Em ratos, a dopamina aumenta a captação da glucose in vivo nos tecidos sensíveis à insulina. Ex vivo, induz, via D2R, a captação de glicose no fígado e potencia a captação da glucose mediada pela insulina no tecido adiposo. No tecido adiposo, aumenta a oxidação lipídica após inibição do D2R (efeito D1R). No homem, a expressão do DRD4 e do DRD1 é menor no TAV dos doentes obesos com IR correlacionando-se com menor expressão dos genes UCP1, PPARA e do INSR. Nos ratos tratados com bromocriptina observou-se o aumento do D1R e TH no fígado e TAE. Observou-se uma diminuição da gordura hepática, bem como um aumento dos níveis totais de GLUT4 e PPARγ e da fosforilação do recetor de insulina (IR-Tyr1631) bem como da AMPK-Thr172 e ATP citrato lyase-Ser455 no TAE. Conclusão: A dopamina regula diretamente a captação de glicose e o metabolismo lipídico no fígado e tecido adiposo. A menor expressão do DRD1 no TAV dos doentes com IR correlaciona-se com a desregulação metabólica. A bromocriptina restaura os níveis de D1R e TH no fígado e TAE de animais diabéticos obesos, o que poderá contribuir para as alterações do metabolismo lipídico e da sensibilidade à insulina. A sinalização dopaminérgica periférica poderá constituir um alvo terapêutico nas doenças metabólicas.